Preventing Non-communicable diseases through Precision Biotherapeutics

Context

Non-communicable diseases (NCDs) cause the majority of deaths in India. Advances in genomics, gene editing, mRNA therapies, biologics and AI have created a field called precision biotherapeutics that aims to treat disease by targeting its biological cause.

What are Non-communicable diseases?

Non-communicable diseases (NCDs) are long-term, chronic illnesses that do not spread from person to person. They usually develop slowly and are caused by a combination of genetic, lifestyle, and environmental factors.

What are Precision Biotherapeutics?

Precision biotherapeutics are medical treatments designed for a patient’s specific genetic, molecular or cellular profile rather than a one-size-fits-all drug. Key technologies:

1. Genomic and proteomic analysis: Reading a person’s DNA and protein patterns to find disease-causing changes.
2. Gene editing (e.g., CRISPR): Fixing a faulty gene so the disease cause is corrected rather than just treated.
3. mRNA and nucleic-acid therapies: Giving cells instructions (via RNA) to make helpful proteins or stop harmful ones.
4. Monoclonal antibodies & biologics: Lab-made molecules that attach to specific disease targets (e.g., a cancer marker).
5. Cell therapies (e.g., CAR-T): Reprogramming a patient’s immune cells to attack disease cells.
6. AI-driven drug discovery: Using large data and machine learning to design better drugs faster.

These tools together let doctors move from symptom control to cause correction, and from reactive treatment to predictive and preventive care.

Why India Needs Precision Biotherapeutics?

1. High NCD burden: Around 65% of deaths in India are due to NCDs — a major public health crisis.
2. Genetic diversity: India’s population has wide genetic variety; drugs developed elsewhere may not work equally here.
3. Potential for personalised prevention: Precision tools can identify high-risk individuals early (predictive care) and prevent disease progression.
4. Economic advantage: India’s strong IT, data analytics, and skilled biotech workforce can lower costs and scale affordable therapies.
5. Global competitiveness: Developing local solutions reduces dependence on imports and creates biotech jobs.

Where India Stands Today

1. Government focus: The Department of Biotechnology lists precision biotherapeutics among priority areas under national biotech policy.
2. Research institutions: Organisations such as IGIB, NIBMG, and THSTI map genetics and disease links in Indian populations. Programs like IndiGen and GenomeIndia build national genomic data resources.
3. Industry activity: Indian firms (e.g., Biocon Biologics, Reddy’s, ImmunoACT, 4baseCare, Akrivia) are investing in biosimilars, monoclonal antibodies, CAR-T, precision diagnostics and oncology tools.
4. Gaps and limits:
   1. Regulation: No clear, detailed regulatory framework for gene, cell and advanced therapies yet.
   2. Manufacturing: Limited domestic capacity for complex biologics and cell therapies.
   3. Access & cost: High prices make many precision treatments unaffordable and currently concentrated in urban centres.
   4. Data protection: Weak legal safeguards for genomic privacy and consent are unresolved.

How Precision Biotherapeutics Can Prevent and Manage NCDs

1. Prediction & Screening: Use genomic profiling to identify people at high risk of diabetes, heart disease or cancers and offer targeted lifestyle or medical prevention.
2. Early Intervention: Apply gene-based or molecular therapies early to correct biological pathways before disease becomes severe.
3. Personalised Treatment: Select drugs (biologics, targeted therapies) that match a patient’s molecular profile, improving success and reducing side effects.
4. Monitoring & AI: Use AI tools to analyse health data continuously and adjust treatment plans in real time.
5. Affordable scale: Local R&D, manufacturing and simplified regulatory pathways can reduce costs and increase access.

Implications

1. Better outcomes: Targeted treatments can reduce complications, hospital stays and long-term care needs for NCD patients.
2. Healthcare shift: Move from reactive to predictive-preventive-personalised care models.
3. Economic gains: A domestic precision-therapy industry can create high-value jobs and export opportunities.
4. Equity risks: Without policy action, benefits may be limited to wealthy urban patients, widening health inequality.
5. Ethical concerns: Misuse of genetic data or discrimination based on genetic risk must be prevented.

Challenges & Way Forward

Conclusion

Precision biotherapeutics can transform India’s fight against NCDs by predicting risk, preventing illness, and offering customised cures that correct disease causes. To realise this promise India must build clear rules, scale manufacturing, protect genomic privacy, and make therapies affordable and widely available.